non-Hodgkin lymphoma

Allogene gives first look at an 'off the shelf' cell therapy for lymphoma
Allogene gives first look at an 'off the shelf' cell therapy for lymphoma
BioPharma Dive
Allogene
ASCO 2020
cell therapy
non-Hodgkin lymphoma
ALLO-501
ALLO-647
Flag link:
ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts
ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts
Fierce Biotech
Roche
ASH2019
non-Hodgkin lymphoma
mosunetuzumab
Flag link:
Morphosys to take on CAR-Ts in NHL with promising antibody
Morphosys to take on CAR-Ts in NHL with promising antibody
Pharmaforum
MorphoSys
Celgene
Revlimid
non-Hodgkin lymphoma
clinical trials
tafasitamab
Flag link:
Preclinical data on MD Anderson Cancer Center-developed drug offers hope for Imbruvica-resistant mantle cell lymphoma patients
Preclinical data on MD Anderson Cancer Center-developed drug offers hope for Imbruvica-resistant mantle cell lymphoma patients
Endpoints
Imbruvica
non-Hodgkin lymphoma
mantle cell lymphoma
JNJ
MD Anderson Cancer Center
Flag link:
Potential Cancer "Vaccine" Shows Promise in Early-Stage NHL Trial
Potential Cancer "Vaccine" Shows Promise in Early-Stage NHL Trial
BioSpace
vaccines
cancer vaccines
Mount Sinai
non-Hodgkin lymphoma
clinical trials
Flag link:
Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
CP Wire
TrovaGene
Onvansertib
AML
mCRPC
non-Hodgkin lymphoma
triple negative breast cancer
Flag link:
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Fierce Pharma
Celgene
Revlimid
clinical trials
Roche
Rituxan
non-Hodgkin lymphoma
Flag link: